Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Prelude Therapeutics Incorporated stock

Own Prelude Therapeutics Incorporated stock in just a few minutes.

Prelude Therapeutics Incorporated is a biotechnology business based in the US. Prelude Therapeutics Incorporated shares (PRLD) are listed on the NASDAQ and all prices are listed in US Dollars. Prelude Therapeutics Incorporated employs 68 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Prelude Therapeutics Incorporated

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PRLD – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Prelude Therapeutics Incorporated share price

Use our graph to track the performance of PRLD stocks over time.

Prelude Therapeutics Incorporated shares at a glance

Information last updated 2021-04-23.
52-week range$23.69 - $95.38
50-day moving average $45.33
200-day moving average $55.82
Wall St. target price$62.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Prelude Therapeutics Incorporated shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Prelude Therapeutics Incorporated stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Prelude Therapeutics Incorporated financials

Gross profit TTM $0
Return on assets TTM -29.93%
Return on equity TTM -49.67%
Profit margin 0%
Book value N/A
Market capitalisation $1.9 billion

TTM: trailing 12 months

Shorting Prelude Therapeutics Incorporated shares

There are currently 1.7 million Prelude Therapeutics Incorporated shares held short by investors – that's known as Prelude Therapeutics Incorporated's "short interest". This figure is 24.5% up from 1.4 million last month.

There are a few different ways that this level of interest in shorting Prelude Therapeutics Incorporated shares can be evaluated.

Prelude Therapeutics Incorporated's "short interest ratio" (SIR)

Prelude Therapeutics Incorporated's "short interest ratio" (SIR) is the quantity of Prelude Therapeutics Incorporated shares currently shorted divided by the average quantity of Prelude Therapeutics Incorporated shares traded daily (recently around 223851.5625). Prelude Therapeutics Incorporated's SIR currently stands at 7.68. In other words for every 100,000 Prelude Therapeutics Incorporated shares traded daily on the market, roughly 7680 shares are currently held short.

To gain some more context, you can compare Prelude Therapeutics Incorporated's short interest ratio against those of similar companies.

However Prelude Therapeutics Incorporated's short interest can also be evaluated against the total number of Prelude Therapeutics Incorporated shares, or, against the total number of tradable Prelude Therapeutics Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Prelude Therapeutics Incorporated's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Prelude Therapeutics Incorporated shares in existence, roughly 40 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Prelude Therapeutics Incorporated shares, roughly 0 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Prelude Therapeutics Incorporated.

Find out more about how you can short Prelude Therapeutics Incorporated stock.

Prelude Therapeutics Incorporated share dividends

We're not expecting Prelude Therapeutics Incorporated to pay a dividend over the next 12 months.

Prelude Therapeutics Incorporated overview

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; and PRT-K4 that is in preclinical stage for solid tumors. Prelude Therapeutics Incorporated was incorporated in 2016 and is headquartered in Wilmington, Delaware. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site